| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 06 Nov 2026 | SCHEDULE 13D/A |
| 06 Nov 2026 |
Form 4: Baker Bros. Advisors Lp, Director and 5 others
Bought 15,666 shares ($5.76M) · Bought 76,140 shares ($29.3M) |
| 06 Nov 2026 |
Form 4: Kelley Shannon T, General Counsel
Sold 1,077 shares ($431K) |
| 06 Nov 2026 | 144 |
| 03 Nov 2026 | 10-Q |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
CONSHOHOCKEN, Pa., Nov. 3, 2026 – Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarte... |
| 28 Sep 2026 | 144 |
| 11 Sep 2026 |
Form 4: Sibold William John, Director
Sold 6,362 shares ($3.41M) · Sold 5,221 shares ($2.83M) |
| 11 Sep 2026 | 144 |
| 09 Sep 2026 | 144 |
| 20 Aug 2026 |
Form 4: Kelley Shannon T, General Counsel
Sold 664 shares ($342K) |
| 20 Aug 2026 | 144 |
| 18 Aug 2026 |
Form 4: Reed John C, Director
Received 647 shares as a grant or award · Granted 1,078 Stock Option (Right to Buy) |
| 18 Aug 2026 |
Form 3: Reed John C, Director
No securities owned |
| 12 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
CONSHOHOCKEN, Pa., August 12, 2026 – Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has ... |
| 30 Jul 2026 | 10-Q |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
CONSHOHOCKEN, Pa., July 30, 2026 – Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports second-quar... |
| 29 Jul 2026 | SCHEDULE 13G/A |
| 20 Jul 2026 |
Form 4: Sibold William John, Director
Received 50,000 shares by exercise or conversion · Sold 2,500 shares ($1.37M) |
Loading...